| Primary |
| Candidiasis |
24.5% |
| Vulvovaginal Candidiasis |
14.8% |
| Fungal Infection |
8.2% |
| Antifungal Treatment |
5.1% |
| Vulvovaginal Mycotic Infection |
5.1% |
| Vaginal Infection |
4.6% |
| Vaginal Candidiasis |
4.1% |
| Oral Candidiasis |
3.6% |
| Oral Fungal Infection |
3.6% |
| Product Used For Unknown Indication |
3.6% |
| Tinea Pedis |
3.1% |
| Vulvovaginitis |
3.1% |
| Contraception |
2.6% |
| Prophylaxis |
2.6% |
| Antibiotic Prophylaxis |
2.0% |
| Diabetes Mellitus |
2.0% |
| Diverticulitis |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Dysphagia |
2.0% |
| Ear Infection Fungal |
1.5% |
|
| Vaginal Haemorrhage |
39.5% |
| Drug Ineffective |
7.9% |
| Hypersensitivity |
7.3% |
| Maternal Drugs Affecting Foetus |
4.5% |
| Candidiasis |
4.0% |
| Genital Haemorrhage |
4.0% |
| Haemorrhage |
4.0% |
| Drug Exposure During Pregnancy |
2.8% |
| Limb Reduction Defect |
2.8% |
| Swollen Tongue |
2.8% |
| Vaginal Discharge |
2.8% |
| Abortion Induced |
2.3% |
| Product Quality Issue |
2.3% |
| Pruritus |
2.3% |
| Rash |
2.3% |
| Back Pain |
1.7% |
| Feeling Hot |
1.7% |
| Metrorrhagia |
1.7% |
| Swelling Face |
1.7% |
| Vulvovaginal Burning Sensation |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
31.0% |
| Drug Use For Unknown Indication |
25.6% |
| Hypertension |
6.0% |
| Candidiasis |
4.3% |
| Dyspepsia |
4.0% |
| Hyperemesis Gravidarum |
3.9% |
| Fungal Infection |
2.4% |
| Foetal Exposure During Pregnancy |
2.2% |
| Depression |
1.9% |
| Epilepsy |
1.9% |
| Hiv Infection |
1.9% |
| Hysterectomy |
1.9% |
| Migraine |
1.9% |
| Muscle Spasms |
1.9% |
| Seasonal Affective Disorder |
1.7% |
| Asthma |
1.6% |
| Contraception |
1.5% |
| Glioblastoma Multiforme |
1.5% |
| Pain |
1.5% |
| Bronchitis |
1.4% |
|
| Metrorrhagia |
12.5% |
| Vestibular Disorder |
12.5% |
| Swelling Face |
11.4% |
| Maternal Exposure During Pregnancy |
6.8% |
| Rash Pruritic |
6.8% |
| Peritonitis |
5.7% |
| Drug Hypersensitivity |
4.5% |
| Pruritus |
4.5% |
| Vaginal Haemorrhage |
4.5% |
| Kidney Malformation |
3.4% |
| Plantar Fasciitis |
3.4% |
| Sinus Bradycardia |
3.4% |
| Spina Bifida Occulta |
3.4% |
| Swelling |
3.4% |
| Abdominal Discomfort |
2.3% |
| Abortion Spontaneous |
2.3% |
| Anaphylactic Shock |
2.3% |
| Back Pain |
2.3% |
| Drug Exposure During Pregnancy |
2.3% |
| Foetal Exposure During Pregnancy |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
43.9% |
| Drug Use For Unknown Indication |
19.3% |
| Pain |
4.9% |
| Hypertension |
3.4% |
| Prophylaxis |
3.2% |
| Hiv Infection |
2.8% |
| Depression |
2.5% |
| Asthma |
1.8% |
| Diabetes Mellitus |
1.8% |
| Constipation |
1.7% |
| Anxiety |
1.7% |
| Multiple Myeloma |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Breast Cancer |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Insomnia |
1.4% |
| Subcutaneous Abscess |
1.4% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Nausea |
1.3% |
|
| Vomiting |
13.3% |
| Weight Decreased |
10.6% |
| Pyrexia |
6.5% |
| Weight Increased |
6.3% |
| Urinary Tract Infection |
6.0% |
| Sepsis |
5.8% |
| Renal Failure Acute |
5.5% |
| Death |
4.8% |
| Dizziness |
4.1% |
| Pain |
4.1% |
| Respiratory Failure |
3.9% |
| Myocardial Infarction |
3.6% |
| Renal Failure |
3.6% |
| Wound Infection Staphylococcal |
3.4% |
| Drug Ineffective |
3.1% |
| Pruritus |
3.1% |
| Pulmonary Embolism |
3.1% |
| Vasculitis |
3.1% |
| Vision Blurred |
3.1% |
| Febrile Neutropenia |
2.9% |
|
| Interacting |
| Acute Myeloid Leukaemia |
12.5% |
| Anxiety |
12.5% |
| Bone Pain |
12.5% |
| Ear Infection |
12.5% |
| Fungal Infection |
12.5% |
| Oral Candidiasis |
12.5% |
| Product Used For Unknown Indication |
12.5% |
| Prophylaxis Of Nausea And Vomiting |
12.5% |
|
| Drug Interaction |
25.0% |
| Neutropenia |
25.0% |
| Suicidal Ideation |
25.0% |
| Weight Decreased |
25.0% |
|
